Developer docs
API playgroundTry for free, no card

Search company profiles

VolitionRx

Full company profile

uuid0000zkc

Namestring
VolitionRx
Legal namestring
VolitionRx Limited
Websiteurl
volition.com
Company typeenum
Public
Founded yearint
2010
Descriptiontext

VolitionRx Limited is a multi-national diagnostics company founded in 2010 and listed on NYSE American (ticker VNRX) that develops blood-based tests built on its patented Nucleosomics platform, which isolates and quantifies circulating nucleosomes to detect disease-associated epigenetic changes from the earliest stages of cancer, sepsis, and NETosis-associated conditions. Its commercial product portfolio spans veterinary cancer screening (Nu.Q Vet Cancer Test, sold through Antech, IDEXX, Fujifilm Vet Systems and other labs), human-health diagnostics (CE-marked Nu.Q NETs for NETosis/sepsis in 30+ European jurisdictions; Nu.Q Cancer blood-based assays; pipeline Capture-Seq liquid biopsy technology achieving >99% ctDNA purity), and research tools (Nu.Q Discover assays and recombinant nucleosomes sold via the rNuQ webshop to ~100 pharma and diagnostic clients).

The company monetizes through a mix of product sales (veterinary kits, research assays, CE-marked kits), licensing and royalty arrangements (Werfen, Hologic, and ongoing discussions with over a dozen diagnostic majors), milestone payments (including a $5M payment tied to a feline lymphoma manuscript), and non-dilutive regional grants (European Regional Development Fund, Walloon Government, Namur Invest). Go-to-market combines distributor networks for veterinary, OEM/platform licensing for human health, direct engagement with hospitals and academic centers (Mayo Clinic, Amsterdam UMC, Hospices Civils de Lyon), and an e-commerce webshop for research reagents.

Operationally, VolitionRx is headquartered in Henderson, Nevada with a 20,000 sq ft purpose-built R&D facility in Gembloux, Belgium, and additional offices in Carlsbad (CA), London, and Singapore; it employs over 80 staff. The business is pre-profitability with FY2025 revenue of $1.7M (40% YoY growth) against operating losses in the $20-30M range, a current ratio of 0.33, $11.7M of total debt, and an active NYSE American compliance plan through August 2027; capital is sourced from repeated dilutive public offerings and Belgian regional grants, with a €2M non-dilutive award closed in March 2026.

Short descriptiontext

VolitionRx is a publicly-traded diagnostics company that develops blood-based Nucleosomics tests for early detection of cancer, sepsis, and NETosis-associated diseases, serving veterinary clinics (via Antech, IDEXX, Fujifilm), hospitals (Mayo Clinic, Amsterdam UMC), and pharmaceutical researchers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHenderson, United States
HQ citystring
Henderson
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
blood-based diagnostics, cancer screening tests, veterinary cancer diagnostics, nucleosome quantification assays, sepsis diagnostic solutions
Industry3 codes
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Cancer Diagnostics
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Product Sales — Veterinary Diagnostics
TypeOne Time License
Description

Revenue from sale of Nu.Q Vet Cancer Tests distributed through Antech, IDEXX, Fujifilm Vet Systems, and other laboratory providers in the US and Asia. Q1 2026 revenue of $1.0M driven by deferred revenue recognition from Heska agreement.

aijourn.com
2Product Sales — Nu.Q Discover / Research Assays
TypeOne Time License
Description

Sale of Nu.Q Discover assays and recombinant nucleosomes (rNuQ) to pharmaceutical and diagnostic companies for research use. The company launched an rNuQ webshop for direct sales. Reported 86% revenue growth for Nu.Q Discover in 2025.

volition.com
3Product Sales — Nu.Q NETs CE-marked Assay
TypeOne Time License
Description

Sales of CE-marked Nu.Q NETs automated assay for clinical use in detecting NETosis-associated conditions. Commercially available across 27 EU member states, three EEA countries, and the UK.

volition.com
4Licensing Agreements
TypeLicensing Royalties
Description

Multi-pillar licensing agreements with Werfen (Antiphospholipid Syndrome) and Hologic (Co-Marketing and Services Agreement), plus ongoing licensing discussions with over a dozen global diagnostic leaders. Expected to generate upfront milestone payments, royalties, and recurring revenue.

volition.com
5Milestone Payments
TypeLicensing Royalties
Description

Contractual milestone payments triggered by clinical and commercial achievements, including $5 million expected upon peer-reviewed publication of Nu.Q Vet feline lymphoma assay manuscript.

stocktitan.net
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels8 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1Nu.Q
Description

Proprietary nucleosome quantification technology platform for early disease detection including cancer and sepsis diagnostics

volition.com
+6 more records
Core offering1 text field

VolitionRx develops and commercializes proprietary Nucleosomics-based blood diagnostic tests that detect epigenetic changes in circulating nucleosomes for early diagnosis of cancer, sepsis, and NETosis-associated diseases. The company sells the CE-marked Nu.Q NETs assay for human sepsis diagnostics, the Nu.Q Vet Cancer Test for canine cancer screening, research-use Nu.Q Discover assays and rNuQ recombinant nucleosomes, and is developing pipeline products including Nu.Q Cancer blood tests and Capture-Seq ctDNA liquid biopsy technology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Q1 2026 revenue of $1.0 million, representing 300% increase year-over-year
+5 more records
Product overview1 text field

VolitionRx offers a diversified portfolio of diagnostic products and services built on its proprietary Nucleosomics™ technology platform. The core Nu.Q® technology detects characteristic epigenetic changes in nucleosomes from blood samples for disease detection. Commercial products include Nu.Q® NETs (CE-marked sepsis diagnostic), Nu.Q® Vet Cancer Test (veterinary cancer screening for dogs), and Nu.Q® Discover (research assays for drug developers including rNuQ recombinant nucleosomes). Pipeline products include Nu.Q® Cancer (human cancer blood tests in development) and Capture-Seq™ (liquid biopsy technology achieving 99%+ ctDNA purity for early cancer detection). The portfolio spans veterinary and human health applications, with products ranging from commercialized diagnostics to research tools and emerging technologies.

Product and service7 records
1Nu.Q Vet Cancer Test
CategoryVeterinary Diagnostics
Description

Affordable, accessible blood test for early detection of cancer in dogs. Simple, cost-effective screening recommended for older dogs (7+ years) and high-risk breeds (4+ years). Available in the US, Europe, Australia, and Asia via distributors including Antech and IDEXX.

2Nu.Q NETs Assay
CategoryHuman Health Diagnostics
Description

CE-marked diagnostic solution that detects NETosis by quantifying circulating Neutrophil Extracellular Traps (NETs) as biomarkers. The only analytically validated assay to quantify NET levels, used for sepsis detection, disease severity prediction, and treatment monitoring. Available across 27 EU member states, 3 EEA countries, and the UK.

3Nu.Q Discover Assays
CategoryResearch Reagents / Research Services
Description

Research service providing drug developers and scientists access to proprietary assays for rapid epigenetic profiling in disease model development, preclinical testing, and clinical studies. Includes H3.1 Research Use Only Assay and recombinant nucleosome products.

4rNuQ Recombinant Nucleosomes
CategoryResearch Reagents
Description

Ready-to-use recombinant nucleosomes for research purposes, manufactured in ISO 13485 certified facility. Includes exclusive H3K18lactylations nucleosomes not available elsewhere. Sold via rNuQ webshop.

5Nu.Q Cancer Blood-Based Assays
CategoryHuman Health Diagnostics - Pipeline
Description

Range of simple, cost-effective blood-based assays for cancer detection with potential applications beyond cancer detection. Focus areas include monitoring disease progression, treatment response, and minimal residual disease monitoring. Working with hospitals in Europe and Asia.

6Capture-Seq Liquid Biopsy Technology
CategoryHuman Health Diagnostics - Pipeline
Description

Novel liquid biopsy method designed to isolate and analyze pure circulating tumor-derived DNA (ctDNA) from blood samples. Achieved over 99% purity in isolating ctDNA and detects over 95% of early-stage cancers.

7Nu.Q NETs Ebola Triage Test (Patent Application)
CategoryHuman Health Diagnostics - Pipeline
Description

Patent-stage product application of Nu.Q NETs test for triaging and monitoring Ebola patients, measuring circulating nucleosomes and Neutrophil Extracellular Traps as early indicators of hyper-inflammation leading to septic shock. Includes lateral flow finger-prick variant for bedside deployment in resource-constrained outbreak zones.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-17
Description

VolitionRx announced a collaboration with Sysmex Corporation to optimize its Nu.Q NETs H3.1 assay on Sysmex's diagnostic platform for detecting Neutrophil Extracellular Traps associated with sepsis and other conditions. The companies have completed assay transfer and begun optimization, with VolitionRx estimating a $3.8 billion total addressable market for the test. Financial terms were not disclosed.

2Fujifilm Vet Systems
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-06
Description

VolitionRx completed validation of its automated Nu.Q Vet Cancer Test with Fujifilm Vet Systems in Japan, enabling full automation instead of manual plates in central laboratories across the country. Over 1,700 veterinary hospitals are already registered to use the test in Japan's market of approximately seven million pet dogs. The automated test runs on the IDS i10 platform, creating operational synergies across the company's technology portfolio.

stocktitan.net
3Medical & Biological Laboratories (MBL)
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-10
Description

VolitionRx appointed Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor of its Nu.Q Discover assays in Japan. MBL, established 1969 as Japan's first antibody manufacturer, specializes in diagnostic reagents with focus on autoimmune diseases. Volition expects significant revenue growth for Nu.Q Discover in 2026 following strong 2025 performance.

prnewswire.com
4Hospices Civils de Lyon
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-30
Description

Hospices Civils de Lyon, France's second-largest university hospital system, is providing active support for VolitionRx's Nu.Q Cancer reimbursement submission to French government agencies under the RIHN framework for innovative medical procedures. Reimbursement determination is targeted within five months of dossier admissibility, with routine clinical use targeted by Q4 2026.

prnewswire.com
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-20
Description

VolitionRx expanded access to its Nu.Q Vet Cancer Test through new laboratory providers — Midwest Veterinary Laboratory in the US and Bioguard in Asia — improving early canine cancer detection in these regions.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

VolitionRx's Q1 2026 revenue growth of 300% was driven by deferred revenue recognition from its Nu.Q Vet agreement with Heska. The agreement contributed to $1.0 million in Q1 2026 revenue.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

VolitionRx signed a licensing agreement with Werfen for Antiphospholipid Syndrome diagnostics, one of multiple multi-billion-dollar diagnostic companies engaged in licensing deals with VolitionRx.

Strategic tierCoreTypeGTM or Marketing Partner
Description

VolitionRx entered a Co-Marketing and Services Agreement with Hologic, a multi-billion-dollar diagnostic company, as part of its commercial expansion strategy.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Mayo Clinic collaborated on clinical studies demonstrating elevated nucleosome levels in trauma patients (674 patients), new clinical use cases for Nu.Q NETs assay in Hidradenitis Suppurativa management, and broader clinical validation across multiple disease areas. The collaboration has produced published peer-reviewed research supporting the platform's clinical utility.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Large-scale study (4,000+ samples, 1,700+ ICU patients) led by Dr. Lieuwe Bos at Amsterdam UMC to assess Nu.Q NETs assay for sepsis diagnosis and monitoring. Results presented at ISICEM 2025 and published peer-reviewed in Critical Care (BMC, Springer Nature).

11German SepNet Study Group / Professor Michael Bauer
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Retrospective analysis of 1,000 ICU patient samples led by Professor Michael Bauer at Jena University Hospital to assess Nu.Q NETs assay for sepsis monitoring. Results published at ESICM 2024 with manuscript submitted for peer review.

investing.com
12Professor Djillali Annane / RHU RECORDS
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Nu.Q NETs assay used in RHU RECORDS study (1,500 patients) led by Professor Djillali Annane in France to identify eligible patients for corticosteroid therapy in sepsis management and establish decision-making thresholds. Interim analysis presented at ISICEM 2025, study due to complete in 2025.

investing.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Santersus AG is developing NucleoCapture technology for cleansing blood of NETs as a sepsis treatment, using Nu.Q NETs within animal and human trials to measure treatment response.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Exact Sciences develops Cologuard and Oncotype blood- and stool-based cancer diagnostics for early detection and treatment monitoring. It is a direct competitor in blood-based multi-cancer screening, sharing VolitionRx's core thesis of non-invasive cancer detection via liquid biopsy.

TypeDirect peer
Description

Guardant Health is a leading liquid biopsy company offering blood-based cancer detection and monitoring assays (Guardant360, Shield). It competes directly with VolitionRx's Nu.Q Cancer and Capture-Seq products in the blood-based cancer diagnostics market.

TypeDirect peer
Description

Natera provides cell-free DNA-based blood tests for oncology (Signatera), transplant monitoring, and reproductive health. Its oncology liquid biopsy franchise directly overlaps with VolitionRx's cancer detection and minimal residual disease monitoring use cases.

TypeDirect peer
Description

Bio-Techne offers proprietary life science research reagents, including recombinant nucleosomes and epigenetic assay kits. Its research-use reagent business directly overlaps with VolitionRx's Nu.Q Discover and rNuQ recombinant nucleosome product lines serving pharma and academic researchers.

5GRAIL
TypeEmerging player
Description

GRAIL is developing Galleri, a multi-cancer early detection test using methylation-based ctDNA analysis. It targets the same blood-based multi-cancer screening market as VolitionRx with a larger commercial and clinical development budget.

TypeBroad incumbent
Description

Hologic is a major diagnostics company with a broad women's health and molecular diagnostics portfolio. It has a co-marketing agreement with VolitionRx and competes broadly in IVD markets where VolitionRx's CE-marked and pipeline products are positioned.

TypeBroad incumbent
Description

QIAGEN is a global leader in sample preparation and molecular diagnostics technologies used in oncology, infectious disease, and research. Its ctDNA and liquid biopsy sample-prep technologies and IVD licensing model are highly comparable to VolitionRx's Capture-Seq and licensing-to-diagnostic-leaders strategy.

TypeBroad incumbent
Description

Bio-Rad is a major life science and clinical diagnostics company offering molecular biology reagents, digital PCR, and IVD products. Its molecular diagnostics and life science research tools portfolio overlaps with both VolitionRx's Nu.Q research assays and IVD ambitions.

TypeBroad incumbent
Description

Sysmex is a global leader in hematology and clinical diagnostics instrumentation. It is both a partner (optimizing Nu.Q NETs H3.1 on Sysmex platforms) and a broad incumbent operating in the same sepsis and hematology diagnostic markets VolitionRx targets with Nu.Q NETs.

TypeEmerging player
Description

Freenome is an emerging liquid biopsy company developing blood-based multi-cancer screening tests using multiomics approaches. It targets the same multi-cancer early detection market as VolitionRx's Nu.Q Cancer and Capture-Seq.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds20 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VolitionRx

Cancer Diagnosticsvolition.com

VolitionRx is a publicly-traded diagnostics company that develops blood-based Nucleosomics tests for early detection of cancer, sepsis, and NETosis-associated diseases, serving veterinary clinics (via Antech, IDEXX, Fujifilm), hospitals (Mayo Clinic, Amsterdam UMC), and pharmaceutical researchers.

What VolitionRx does

VolitionRx Limited is a multi-national diagnostics company founded in 2010 and listed on NYSE American (ticker VNRX) that develops blood-based tests built on its patented Nucleosomics platform, which isolates and quantifies circulating nucleosomes to detect disease-associated epigenetic changes from the earliest stages of cancer, sepsis, and NETosis-associated conditions. Its commercial product portfolio spans veterinary cancer screening (Nu.Q Vet Cancer Test, sold through Antech, IDEXX, Fujifilm Vet Systems and other labs), human-health diagnostics (CE-marked Nu.Q NETs for NETosis/sepsis in 30+ European jurisdictions; Nu.Q Cancer blood-based assays; pipeline Capture-Seq liquid biopsy technology achieving >99% ctDNA purity), and research tools (Nu.Q Discover assays and recombinant nucleosomes sold via the rNuQ webshop to ~100 pharma and diagnostic clients).

The company monetizes through a mix of product sales (veterinary kits, research assays, CE-marked kits), licensing and royalty arrangements (Werfen, Hologic, and ongoing discussions with over a dozen diagnostic majors), milestone payments (including a $5M payment tied to a feline lymphoma manuscript), and non-dilutive regional grants (European Regional Development Fund, Walloon Government, Namur Invest). Go-to-market combines distributor networks for veterinary, OEM/platform licensing for human health, direct engagement with hospitals and academic centers (Mayo Clinic, Amsterdam UMC, Hospices Civils de Lyon), and an e-commerce webshop for research reagents.

Operationally, VolitionRx is headquartered in Henderson, Nevada with a 20,000 sq ft purpose-built R&D facility in Gembloux, Belgium, and additional offices in Carlsbad (CA), London, and Singapore; it employs over 80 staff. The business is pre-profitability with FY2025 revenue of $1.7M (40% YoY growth) against operating losses in the $20-30M range, a current ratio of 0.33, $11.7M of total debt, and an active NYSE American compliance plan through August 2027; capital is sourced from repeated dilutive public offerings and Belgian regional grants, with a €2M non-dilutive award closed in March 2026.

VolitionRx firmographics

Firmographics
Name
VolitionRx
Legal name
VolitionRx Limited
Website
https://volition.com
Company type
Public
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Short description
VolitionRx is a publicly-traded diagnostics company that develops blood-based Nucleosomics tests for early detection of cancer, sepsis, and NETosis-associated diseases, serving veterinary clinics (via Antech, IDEXX, Fujifilm), hospitals (Mayo Clinic, Amsterdam UMC), and pharmaceutical researchers.
Ownership category
akta.pro rank

VolitionRx industry classification

Industry
Product category
Cancer Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)

Keywords

  • Blood-based diagnostics
  • Cancer screening tests
  • Veterinary cancer diagnostics
  • Nucleosome quantification assays
  • Sepsis diagnostic solutions

Where VolitionRx is headquartered

Location

Headquarters

HQ city
Henderson
HQ country
United States
HQ region
North America

Offices5 records

Markets served

VolitionRx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Product Sales — Veterinary Diagnostics: Revenue from sale of Nu.Q Vet Cancer Tests distributed through Antech, IDEXX, Fujifilm Vet Systems, and other laboratory providers in the US and Asia. Q1 2026 revenue of $1.0M driven by deferred revenue recognition from Heska agreement.
  2. Product Sales — Nu.Q Discover / Research Assays: Sale of Nu.Q Discover assays and recombinant nucleosomes (rNuQ) to pharmaceutical and diagnostic companies for research use. The company launched an rNuQ webshop for direct sales. Reported 86% revenue growth for Nu.Q Discover in 2025.
  3. Product Sales — Nu.Q NETs CE-marked Assay: Sales of CE-marked Nu.Q NETs automated assay for clinical use in detecting NETosis-associated conditions. Commercially available across 27 EU member states, three EEA countries, and the UK.
  4. Licensing Agreements: Multi-pillar licensing agreements with Werfen (Antiphospholipid Syndrome) and Hologic (Co-Marketing and Services Agreement), plus ongoing licensing discussions with over a dozen global diagnostic leaders. Expected to generate upfront milestone payments, royalties, and recurring revenue.
  5. Milestone Payments: Contractual milestone payments triggered by clinical and commercial achievements, including $5 million expected upon peer-reviewed publication of Nu.Q Vet feline lymphoma assay manuscript.

Go-to-market motion2 records

Distribution channels8 records

Marketing channels7 records

VolitionRx product offering

Product offering

Core offering

VolitionRx develops and commercializes proprietary Nucleosomics-based blood diagnostic tests that detect epigenetic changes in circulating nucleosomes for early diagnosis of cancer, sepsis, and NETosis-associated diseases. The company sells the CE-marked Nu.Q NETs assay for human sepsis diagnostics, the Nu.Q Vet Cancer Test for canine cancer screening, research-use Nu.Q Discover assays and rNuQ recombinant nucleosomes, and is developing pipeline products including Nu.Q Cancer blood tests and Capture-Seq ctDNA liquid biopsy technology.

Product overview

VolitionRx offers a diversified portfolio of diagnostic products and services built on its proprietary Nucleosomics™ technology platform. The core Nu.Q® technology detects characteristic epigenetic changes in nucleosomes from blood samples for disease detection. Commercial products include Nu.Q® NETs (CE-marked sepsis diagnostic), Nu.Q® Vet Cancer Test (veterinary cancer screening for dogs), and Nu.Q® Discover (research assays for drug developers including rNuQ recombinant nucleosomes). Pipeline products include Nu.Q® Cancer (human cancer blood tests in development) and Capture-Seq™ (liquid biopsy technology achieving 99%+ ctDNA purity for early cancer detection). The portfolio spans veterinary and human health applications, with products ranging from commercialized diagnostics to research tools and emerging technologies.

Differentiator

Problem solved

Functional benefit

Brands

  • Nu.Q: Proprietary nucleosome quantification technology platform for early disease detection including cancer and sepsis diagnostics
  • Nu.Q NETs
  • Nu.Q Vet
  • Nu.Q Cancer
  • Nu.Q Discover
  • Capture-Seq
  • Nucleosomics

Products and services

  • Nu.Q Vet Cancer Test Affordable, accessible blood test for early detection of cancer in dogs. Simple, cost-effective screening recommended for older dogs (7+ years) and high-risk breeds (4+ years). Available in the US, Europe, Australia, and Asia via distributors including Antech and IDEXX.
  • Nu.Q NETs Assay CE-marked diagnostic solution that detects NETosis by quantifying circulating Neutrophil Extracellular Traps (NETs) as biomarkers. The only analytically validated assay to quantify NET levels, used for sepsis detection, disease severity prediction, and treatment monitoring. Available across 27 EU member states, 3 EEA countries, and the UK.
  • Nu.Q Discover Assays Research service providing drug developers and scientists access to proprietary assays for rapid epigenetic profiling in disease model development, preclinical testing, and clinical studies. Includes H3.1 Research Use Only Assay and recombinant nucleosome products.
  • rNuQ Recombinant Nucleosomes Ready-to-use recombinant nucleosomes for research purposes, manufactured in ISO 13485 certified facility. Includes exclusive H3K18lactylations nucleosomes not available elsewhere. Sold via rNuQ webshop.
  • Nu.Q Cancer Blood-Based Assays Range of simple, cost-effective blood-based assays for cancer detection with potential applications beyond cancer detection. Focus areas include monitoring disease progression, treatment response, and minimal residual disease monitoring. Working with hospitals in Europe and Asia.
  • Capture-Seq Liquid Biopsy Technology Novel liquid biopsy method designed to isolate and analyze pure circulating tumor-derived DNA (ctDNA) from blood samples. Achieved over 99% purity in isolating ctDNA and detects over 95% of early-stage cancers.
  • Nu.Q NETs Ebola Triage Test (Patent Application) Patent-stage product application of Nu.Q NETs test for triaging and monitoring Ebola patients, measuring circulating nucleosomes and Neutrophil Extracellular Traps as early indicators of hyper-inflammation leading to septic shock. Includes lateral flow finger-prick variant for bedside deployment in resource-constrained outbreak zones.

Quantifiable outcome

  • Q1 2026 revenue of $1.0 million, representing 300% increase year-over-year
  • +5 more outcomes

Companies that use VolitionRx

Customer profile

Named customers9 records

Segments4 records

Ideal customer profiles4 records

VolitionRx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

VolitionRx partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and minor.

  • Sysmex CorporationcoreTechnology or Integration · 17 June 2026VolitionRx announced a collaboration with Sysmex Corporation to optimize its Nu.Q NETs H3.1 assay on Sysmex's diagnostic platform for detecting Neutrophil Extracellular Traps associated with sepsis and other conditions. The companies have completed assay transfer and begun optimization, with VolitionRx estimating a $3.8 billion total addressable market for the test. Financial terms were not disclosed.
  • Fujifilm Vet SystemscoreChannel Partner/ Reseller/ Distributor · 6 March 2026VolitionRx completed validation of its automated Nu.Q Vet Cancer Test with Fujifilm Vet Systems in Japan, enabling full automation instead of manual plates in central laboratories across the country. Over 1,700 veterinary hospitals are already registered to use the test in Japan's market of approximately seven million pet dogs. The automated test runs on the IDS i10 platform, creating operational synergies across the company's technology portfolio.
  • Medical & Biological Laboratories (MBL)minorChannel Partner/ Reseller/ Distributor · 10 February 2026VolitionRx appointed Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor of its Nu.Q Discover assays in Japan. MBL, established 1969 as Japan's first antibody manufacturer, specializes in diagnostic reagents with focus on autoimmune diseases. Volition expects significant revenue growth for Nu.Q Discover in 2026 following strong 2025 performance.
  • Hospices Civils de LyoncoreStrategic or Co-development Partner · 30 January 2026Hospices Civils de Lyon, France's second-largest university hospital system, is providing active support for VolitionRx's Nu.Q Cancer reimbursement submission to French government agencies under the RIHN framework for innovative medical procedures. Reimbursement determination is targeted within five months of dossier admissibility, with routine clinical use targeted by Q4 2026.
  • Midwest Veterinary Laboratory and BioguardminorChannel Partner/ Reseller/ Distributor · 20 January 2026VolitionRx expanded access to its Nu.Q Vet Cancer Test through new laboratory providers — Midwest Veterinary Laboratory in the US and Bioguard in Asia — improving early canine cancer detection in these regions.
  • Heska CorporationcoreChannel Partner/ Reseller/ DistributorVolitionRx's Q1 2026 revenue growth of 300% was driven by deferred revenue recognition from its Nu.Q Vet agreement with Heska. The agreement contributed to $1.0 million in Q1 2026 revenue.
  • WerfencoreOEM/ Whitelabel/ Licensing PartnerVolitionRx signed a licensing agreement with Werfen for Antiphospholipid Syndrome diagnostics, one of multiple multi-billion-dollar diagnostic companies engaged in licensing deals with VolitionRx.
  • HologiccoreGTM or Marketing PartnerVolitionRx entered a Co-Marketing and Services Agreement with Hologic, a multi-billion-dollar diagnostic company, as part of its commercial expansion strategy.
  • Mayo CliniccoreStrategic or Co-development PartnerMayo Clinic collaborated on clinical studies demonstrating elevated nucleosome levels in trauma patients (674 patients), new clinical use cases for Nu.Q NETs assay in Hidradenitis Suppurativa management, and broader clinical validation across multiple disease areas. The collaboration has produced published peer-reviewed research supporting the platform's clinical utility.
  • Amsterdam UMCcoreStrategic or Co-development PartnerLarge-scale study (4,000+ samples, 1,700+ ICU patients) led by Dr. Lieuwe Bos at Amsterdam UMC to assess Nu.Q NETs assay for sepsis diagnosis and monitoring. Results presented at ISICEM 2025 and published peer-reviewed in Critical Care (BMC, Springer Nature).
  • German SepNet Study Group / Professor Michael BauercoreStrategic or Co-development PartnerRetrospective analysis of 1,000 ICU patient samples led by Professor Michael Bauer at Jena University Hospital to assess Nu.Q NETs assay for sepsis monitoring. Results published at ESICM 2024 with manuscript submitted for peer review.
  • Professor Djillali Annane / RHU RECORDScoreStrategic or Co-development PartnerNu.Q NETs assay used in RHU RECORDS study (1,500 patients) led by Professor Djillali Annane in France to identify eligible patients for corticosteroid therapy in sepsis management and establish decision-making thresholds. Interim analysis presented at ISICEM 2025, study due to complete in 2025.
  • Santersus AGminorStrategic or Co-development PartnerSantersus AG is developing NucleoCapture technology for cleansing blood of NETs as a sepsis treatment, using Nu.Q NETs within animal and human trials to measure treatment response.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

VolitionRx competitors and assessment

Company assessment

Direct peers

  • Exact Sciences: Exact Sciences develops Cologuard and Oncotype blood- and stool-based cancer diagnostics for early detection and treatment monitoring. It is a direct competitor in blood-based multi-cancer screening, sharing VolitionRx's core thesis of non-invasive cancer detection via liquid biopsy.
  • Guardant Health: Guardant Health is a leading liquid biopsy company offering blood-based cancer detection and monitoring assays (Guardant360, Shield). It competes directly with VolitionRx's Nu.Q Cancer and Capture-Seq products in the blood-based cancer diagnostics market.
  • Natera: Natera provides cell-free DNA-based blood tests for oncology (Signatera), transplant monitoring, and reproductive health. Its oncology liquid biopsy franchise directly overlaps with VolitionRx's cancer detection and minimal residual disease monitoring use cases.
  • Bio-Techne: Bio-Techne offers proprietary life science research reagents, including recombinant nucleosomes and epigenetic assay kits. Its research-use reagent business directly overlaps with VolitionRx's Nu.Q Discover and rNuQ recombinant nucleosome product lines serving pharma and academic researchers.

Emerging players

  • GRAIL: GRAIL is developing Galleri, a multi-cancer early detection test using methylation-based ctDNA analysis. It targets the same blood-based multi-cancer screening market as VolitionRx with a larger commercial and clinical development budget.
  • Freenome: Freenome is an emerging liquid biopsy company developing blood-based multi-cancer screening tests using multiomics approaches. It targets the same multi-cancer early detection market as VolitionRx's Nu.Q Cancer and Capture-Seq.

Broad incumbents

  • Hologic: Hologic is a major diagnostics company with a broad women's health and molecular diagnostics portfolio. It has a co-marketing agreement with VolitionRx and competes broadly in IVD markets where VolitionRx's CE-marked and pipeline products are positioned.
  • QIAGEN: QIAGEN is a global leader in sample preparation and molecular diagnostics technologies used in oncology, infectious disease, and research. Its ctDNA and liquid biopsy sample-prep technologies and IVD licensing model are highly comparable to VolitionRx's Capture-Seq and licensing-to-diagnostic-leaders strategy.
  • Bio-Rad Laboratories: Bio-Rad is a major life science and clinical diagnostics company offering molecular biology reagents, digital PCR, and IVD products. Its molecular diagnostics and life science research tools portfolio overlaps with both VolitionRx's Nu.Q research assays and IVD ambitions.
  • Sysmex Corporation: Sysmex is a global leader in hematology and clinical diagnostics instrumentation. It is both a partner (optimizing Nu.Q NETs H3.1 on Sysmex platforms) and a broad incumbent operating in the same sepsis and hematology diagnostic markets VolitionRx targets with Nu.Q NETs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

VolitionRx social profiles

Digital presence

VolitionRx compliance and trust

Trust signal

Compliance2 records

VolitionRx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VolitionRx leadership team

Management profile

Number of profiles

Profiles11 records

VolitionRx subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

VolitionRx funding detail

Funding detail

Funding overview

Funding rounds20 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VolitionRx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VolitionRx

What does VolitionRx do?

VolitionRx develops and commercializes proprietary Nucleosomics-based blood diagnostic tests that detect epigenetic changes in circulating nucleosomes for early diagnosis of cancer, sepsis, and NETosis-associated diseases. The company sells the CE-marked Nu.Q NETs assay for human sepsis diagnostics, the Nu.Q Vet Cancer Test for canine cancer screening, research-use Nu.Q Discover assays and rNuQ recombinant nucleosomes, and is developing pipeline products including Nu.Q Cancer blood tests and Capture-Seq ctDNA liquid biopsy technology.

Is VolitionRx a public or private company?

VolitionRx is a public company. It is classified as public and is currently operating.

When was VolitionRx founded?

VolitionRx was founded in 2010. It employs 51 to 100 people.

Where is VolitionRx based?

VolitionRx is headquartered in Henderson, United States, in the North America region.

How does VolitionRx make money?

Five revenue lines are on record. Product Sales — Veterinary Diagnostics are the primary driver. The others are product Sales — Nu.Q Discover / Research Assays, product Sales — Nu.Q NETs CE-marked Assay, licensing Agreements and milestone Payments.

Who are VolitionRx's main competitors?

Direct peers on record are Exact Sciences, Guardant Health, Natera and Bio-Techne. Emerging players are GRAIL and Freenome. Broad incumbents are Hologic, QIAGEN, Bio-Rad Laboratories and Sysmex Corporation.

Does VolitionRx have an API?

No public API is recorded for VolitionRx.

What industry is VolitionRx in?

VolitionRx's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays), with a secondary code of HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewFreedom Broker downgrades VolitionRX to Hold from BuyFreedom Broker downgraded VolitionRX to Hold from Buy. The rating change is reported without additional details on the rationale or price target.Seeking AlphaVolitionRx targets operating cash burn below $1M per month in 2027 as it pushes France sepsis rolloutVolitionRx reported Q3 2026 revenue of $1.6 million and an operating loss of $3.3 million, narrowing from the prior quarter. The company aims to bring operating cash burn below $1 million per month in 2027 and is pushing its Nu.Q platform in France, with reimbursement approval as a key milestone.MoomooVolitionRx Limited Announces Third Quarter 2026 Financial Results and Business UpdateVolitionRx reported Q3 2026 revenue of $1.6 million, up 157% year-over-year, and an operating loss of $3.3 million, down 35%. The company paid off its $7.5 million convertible note and held $2.4 million in cash. It plans a conference call on November 13 to discuss results and upcoming milestones.PR NewswireVolitionRx Limited Announces Third Quarter 2026 Financial Results and Business UpdateVolitionRx reported Q3 2026 revenue of $1.6 million, up 157% year-over-year, and an operating loss of $3.3 million, down 35% from the prior year. The company also prepaid its $7.5 million convertible note and held $2.4 million in cash as of September 30, 2026.MoomooVolitionRx Limited Schedules Third Quarter 2026 Earnings Conference Call and Business UpdateVolitionRx Limited will host a conference call on November 13, 2026, at 8:30 a.m. Eastern Time to discuss its third-quarter 2026 financial and operating results and provide a business update. The call will be hosted by CEO Cameron Reynolds and CFO Terig Hughes, with dial-in numbers and a replay available until November 27.PR NewswireVolitionRx Limited Schedules Third Quarter 2026 Earnings Conference Call and Business UpdateVolitionRx Limited will host a conference call on November 13, 2026, at 8:30 a.m. Eastern Time to discuss its third-quarter 2026 financial and operating results and provide a business update. The call will be hosted by CEO Cameron Reynolds and CFO Terig Hughes, with a live webcast and replay available.American Banking and Market NewsVolitionRX (VNRX) Projected to Release Earnings on ThursdayVolitionRX is expected to report Q3 2026 earnings after market close on Thursday, November 12th, with analysts projecting a loss of $0.35 per share and revenue of $0.71 million. The company's last earnings call missed estimates with a loss of $0.85 per share and revenue of $0.40 million. The stock opened at $0.20, with an average analyst rating of Hold and a target price of $28.00.Business & FinancialNetworknewsbreaks Volitionrx (NYSE American: VNRX) Signs LOI With Missionpharma To Explore Global Development And Commercialization Of Netosis Diagnostic TestVolitionrx signed a letter of intent with Missionpharma to explore global development and commercialization of its Netosis diagnostic test. The test measures circulating nucleosomes and neutrophil extracellular traps as early indicators of hyperinflammation, with applications beyond centralized laboratory testing. The collaboration aims to accelerate access to affordable diagnostic tools in resource-constrained regions.TradingViewVolitionRx Limited (VNRX) Signs LOI to Develop NETosis Lateral Flow TestVolitionRx signed a non-binding LOI with Missionpharma to explore development, manufacturing support, and distribution of its prototype lateral flow test for NETosis. The test targets decentralized use, including low- and middle-income countries and neonatal sepsis triage, with potential low-cost manufacturing assistance.